<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-25988" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Nortriptyline</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Merwar</surname>
            <given-names>Gagindip</given-names>
          </name>
          <aff>Kaweah Delta Hospital</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gibbons</surname>
            <given-names>Jonathan R.</given-names>
          </name>
          <aff>Touro College of Osteopathic Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Hosseini</surname>
            <given-names>Seyed Alireza</given-names>
          </name>
          <aff>Kern Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Saadabadi</surname>
            <given-names>Abdolreza</given-names>
          </name>
          <aff>Western University/ Kaweah Delta</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Gagindip Merwar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Jonathan Gibbons declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Seyed Alireza Hosseini declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abdolreza Saadabadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-25988.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Nortriptyline is indicated for use in the treatment of depression (FDA-approved). It can also be used off-label for conditions such as chronic pain, diabetic neuropathy, myofascial pain, orofacial pain, and postherpetic neuralgia. Nortriptyline has also shown to be useful in patients trying to quit smoking. Nortriptyline is not FDA approved for use in children. This activity covers nortryptyline's indications, mechanism of action, pharmacology, administration, adverse event profiles, eligible patient populations, contraindications, and monitoring, and highlights the role of the interprofessional team in the management of depression and other diseases with nortriptyline therapy.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Outline the mechanism of action of nortriptyline.</p></list-item><list-item><p>Review the indications for using nortriptyline.</p></list-item><list-item><p>Summarize the potential adverse effects associated with nortriptyline therapy.</p></list-item><list-item><p>Describe the importance of improving care coordination among the interprofessional team to enhance the delivery of care for patients who can benefit from therapy with nortriptyline.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25988&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25988">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-25988.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Nortriptyline is indicated for use in the treatment of depression (FDA-approved). Nortriptyline is not FDA approved for use in children.</p>
        <p>Nortriptyline can also be used for the following off-label&#x000a0;indications:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic pain<xref ref-type="bibr" rid="article-25988.r1">[1]</xref>&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Diabetic neuropathy<xref ref-type="bibr" rid="article-25988.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Persistent myofascial pain<xref ref-type="bibr" rid="article-25988.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Trigeminal neuralgia<xref ref-type="bibr" rid="article-25988.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Postherpetic neuralgia<xref ref-type="bibr" rid="article-25988.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Smoking cessation<xref ref-type="bibr" rid="article-25988.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Migraine prophylaxis<xref ref-type="bibr" rid="article-25988.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Neurogenic cough<xref ref-type="bibr" rid="article-25988.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25988.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Nortriptyline is an antidepressant that falls under the pharmacological category of tricyclics (secondary amine), more commonly known as TCAs.The consensus is that nortriptyline inhibits the reuptake of serotonin and norepinephrine by the presynaptic neuronal membrane, thereby increasing the concentration of those neurotransmitters in the synapse. Additionally, nortriptyline inhibits the activity of histamine, 5-hydroxytryptamine, and acetylcholine. Nortriptyline&#x000a0;increases the pressor effect of norepinephrine but hinders the pressor response of phenethylamine. However, research has found additional receptor effects, including desensitization of adenylyl cyclase, down-regulation of beta-adrenergic receptors, and downregulation of serotonin receptors.&#x000a0;</p>
        <p>The proposed mechanism of nortryptyline in neuropathic pain is an increase in noradrenaline levels acting within dorsal root ganglia on &#x003b2;2-adrenoceptors expressed by non-neuronal satellite cells. This stimulation of &#x003b2;2-adrenoreceptors reduces the neuropathy-induced production of TNF&#x003b1;, resulting in the relief of neuropathic pain.<xref ref-type="bibr" rid="article-25988.r9">[9]</xref>&#x000a0;Nortriptyline's mechanism in smoking cessation is unclear, but the possible action may involve simulating the noradrenergic actions of nicotine.<xref ref-type="bibr" rid="article-25988.r10">[10]</xref>&#x000a0;A recent study suggests that nortriptyline can be used as a new antimicrobial drug against multidrug-resistant&#x000a0;<italic toggle="yes">Candida Albicans</italic>&#x000a0;infection by&#x000a0;inhibiting biofilm and ability to kill cells in a mature biofilm efficiently; however, more research is needed.<xref ref-type="bibr" rid="article-25988.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Absorption:</bold> Peak plasma concentrations are 7 to 8.5 hours after oral administration, although antidepressant action is obtained after a few weeks.<xref ref-type="bibr" rid="article-25988.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Distribution:</bold> Nortriptyline is distributed to the brain, heart, and liver. Nortriptyline and its metabolite are highly bound to plasma and tissue proteins. Nortriptyline crosses the placenta, and nortriptyline is present in breast milk.<xref ref-type="bibr" rid="article-25988.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Metabolism:</bold> Nortriptyline, when administered orally, undergoes first-pass metabolism in the liver by CYP2D6.<xref ref-type="bibr" rid="article-25988.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p><bold>Excretion:</bold> The primary route of elimination is urinary excretion, approximately one-third of the dose as metabolites within 24 hours, but it is also excreted in feces via the bile.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25988.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Nortriptyline is usually taken orally as a capsule or an oral solution. Capsule form comes in 10 mg, 25 mg, 50 mg, and 75 mg strengths. The oral solution form is usually of the following composition 10 mg/5 mL (473 mL).&#x000a0;The usual adult dose is 25 mg three or four times daily; it should begin at a low level and increase as needed. As an alternate regimen, the total daily dosage can be given once daily. When doses higher than 100 mg daily are administered, plasma levels of nortriptyline should be monitored. Doses higher than 150 mg daily are not recommended.</p>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patients with Hepatic impairment: </bold>No information has been provided in the manufacturer's product labeling. However, caution and dose reduction are advised in patients with hepatic impairment, given the drug's primary metabolism is by liver enzymes.<xref ref-type="bibr" rid="article-25988.r14">[14]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Patients with Renal impairment: </bold>No information has been provided in the manufacturer's product labeling.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pregnancy Considerations: </bold>According to product labeling,&#x000a0;preclinical studies during pregnancy have been inconclusive.&#x000a0;Safe use of&#x000a0;nortriptyline during pregnancy has not been established; therefore, when the drug is administered to pregnant patients or women of childbearing potential, clinicians must weigh the potential benefits against the possible hazard.</p>
          </list-item>
          <list-item>
            <p>Breastfeeding Considerations: According to product labeling, the safe use of&#x000a0;nortriptyline during lactation has not been established. However, nortriptyline's&#x000a0;concentration in breastmilk is low. Consequently, amounts ingested by the infant are small. However, the less active metabolites are often detectable in low levels in infant serum.&#x000a0;Many reviewers&#x000a0;consider nortriptyline preferred TCA during breastfeeding; however, drugs&#x000a0;that have a better safety profile during lactation are paroxetine and sertraline.<xref ref-type="bibr" rid="article-25988.r13">[13]</xref></p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pharmacogenomic considerations:&#x000a0; </bold>Advancement in the field of pharmacogenomics can be used to deliver effective patient-centered by individualized drug therapy regimens.<xref ref-type="bibr" rid="article-25988.r15">[15]</xref>
<list list-type="bullet"><list-item><p>In&#x000a0;CYP2D6 ultrarapid metabolizer, clinicians should avoid&#x000a0;nortriptyline use due to potential lack of efficacy and consider alternative drugs not metabolized by CYP2D6.</p></list-item><list-item><p>In patients who are CYP2D6 poor metabolizers avoid&#x000a0;nortriptyline&#x000a0;use due to the potential for adverse drug reactions. Clinicians can consider alternative drugs not metabolized by CYP2D6.&#x000a0;Consider a 50% reduction of the recommended starting dose if a TCA is warranted.<xref ref-type="bibr" rid="article-25988.r14">[14]</xref></p></list-item></list>
</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-25988.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Nortriptyline has a black box warning for increased risk of suicide in adolescents, children, and young adults with major depressive disorder and multiple other psychiatric disorders.<xref ref-type="bibr" rid="article-25988.r16">[16]</xref></p>
        <p>The most common adverse effects of nortriptyline include downiness, xerostomia, dizziness, constipation, blurred visions, palpitations, tachycardia, impaired coordination, increased appetite, nausea/vomiting, diaphoresis, weakness, disorientation, confusion, restlessness, insomnia, anxiety/agitation, urinary retention, urinary frequency, rash, urticaria, pruritus, weight gain, libido changes, impotence, gynecomastia, galactorrhea, tremor, hypo/hyperglycemia, paraesthesia, and photosensitivity.<xref ref-type="bibr" rid="article-25988.r17">[17]</xref></p>
        <p>The most serious adverse effects include orthostatic hypotension, HTN, syncope, ventricular arrhythmias, AV block, MI, stroke, paralytic ileus, glaucoma, increased IOP, agranulocytosis, leukopenia, thrombocytopenia, hepatitis, angioedema.<xref ref-type="bibr" rid="article-25988.r18">[18]</xref><xref ref-type="bibr" rid="article-25988.r19">[19]</xref></p>
        <p>Neuropsychiatric adverse drug reactions include EPS symptoms, ataxia, tardive dyskinesia, hallucinations, psychosis exacerbation, hypomania/mania, exacerbation of depression, suicidality, serotonin syndrome, SIADH, hyperthermia, and seizures.<xref ref-type="bibr" rid="article-25988.r20">[20]</xref><xref ref-type="bibr" rid="article-25988.r21">[21]</xref><xref ref-type="bibr" rid="article-25988.r22">[22]</xref></p>
        <p>Cardiotoxicity is the hallmark adverse drug reaction of tricyclic antidepressants, such as nortriptyline. In the case of TCA toxicity, fast cardiac sodium channels are inhibited, which can lead to cardiac arrhythmias. On electrocardiography. A widened QRS complex is often noted.<xref ref-type="bibr" rid="article-25988.r23">[23]</xref></p>
        <p>A patient can also have withdrawal symptoms such as dizziness, gastrointestinal problems such as nausea and vomiting, anxiety, headaches, and restlessness if the patient discontinues nortriptyline abruptly. Clinicians can avoid these withdrawal symptoms by gradually decreasing the dose of nortriptyline over a period.<xref ref-type="bibr" rid="article-25988.r24">[24]</xref></p>
        <p>
<bold>Drug Interactions</bold>
</p>
        <p>Clinicians should avoid concurrent usage of cimetidine and tricyclic antidepressants such as nortriptyline as the drug interaction can increase the concentration of TCAs. Using nortriptyline, along with alcohol, can increase the effects of alcohol on patients. Cytochrome P450 2D6 metabolizes nortriptyline. All pharmacological drugs that inhibit 2D6 can produce an adverse reaction. Significant drug interactions that can inhibit cytochrome P450 2D6 include quinidine and cimetidine. Cimetidine increases bioavailability and decreases the clearance of this drug due to its inhibition of metabolic pathways of both demethylation and hydroxylation, as well as its ability to reduce hepatic extraction of nortriptyline. Other drugs are substrates for CYP2D6, such as other antidepressants, phenothiazines, and type-1C antiarrhythmics such as propafenone and flecainide.<xref ref-type="bibr" rid="article-25988.r25">[25]</xref><xref ref-type="bibr" rid="article-25988.r26">[26]</xref></p>
        <p>Concurrent usage of nortriptyline with drugs that can inhibit cytochrome CYP2D6 may require lower doses than usually prescribed for either nortriptyline or the other medication.</p>
        <p>Many patients prescribed nortriptyline may already be taking SSRIs such as fluoxetine. If the benefit of switching from fluoxetine to nortriptyline is higher than the risk, the clinician should consider that fluoxetine has an active metabolite, norfluoxetine, with a long half-life. The risk of adverse effects and interactions may be high for several weeks after discontinuing fluoxetine. Therefore, usage of nortriptyline with SSRIs like fluoxetine can increase the risk for serotonin syndrome. Fluoxetine should be discontinued for up to six weeks before starting another medication that inhibits serotonin reuptake. If serotonin syndrome occurs, clinicians should promptly administer an antidote, i.e., cyproheptadine. Cyproheptadine is a 5-HT1A, 5-HT2A, and H1 receptor antagonist.<xref ref-type="bibr" rid="article-25988.r27">[27]</xref></p>
      </sec>
      <sec id="article-25988.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Tricyclic antidepressants use along with a monoamine oxidase (MAO) inhibitor, linezolid, and IV methylene blue is contraindicated as they can lead to an increased risk of developing serotonin syndrome. Serotonin syndrome can be life-threatening as it can cause a change in mental status, autonomic instability, neuromuscular changes, seizures, and gastrointestinal symptoms. More importantly, concurrent use of both medications can cause convulsions, hyper-pyretic crises, and death. The patient must discontinue MAO inhibitors for at least 14 days before starting nortriptyline.<xref ref-type="bibr" rid="article-25988.r28">[28]</xref>&#x000a0;If nortriptyline must be used alongside serotonergic drugs such as triptans, other TCAs, fentanyl, lithium, tramadol, buspirone, tryptophan, and St. John&#x02019;s Wort, the benefits must outweigh the risks.</p>
        <p>Postmarketing reports have shown a possible association between nortriptyline and the unmasking of Brugada syndrome. For this reason, patients with confirmed or suspected Brugada syndrome should avoid nortriptyline as it can result in EKG abnormalities, syncope, and even sudden cardiac death.<xref ref-type="bibr" rid="article-25988.r29">[29]</xref>&#x000a0;Nortriptyline can cause pupillary dilation, potentially resulting in an angle-closure attack in an individual with anatomically narrow angles. Finally, nortriptyline is contraindicated during the acute recovery period after myocardial infarction. The use of nortriptyline is also contraindicated in patients with hypersensitivity to nortriptyline or its components. Cross-sensitivity between nortriptyline hydrochloride and other dibenzazepines is a possibility.</p>
      </sec>
      <sec id="article-25988.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>As an antidepressant, the therapeutic range for nortriptyline is between 50 to 150 ng/mL (190 to 570 nmol/L). According to&#x000a0;APA guidelines, patients using nortriptyline need monitoring for suicidal ideation, especially at the start of therapy and when making dosage changes. Clinicians should frequently monitor cardiac parameters such as heart rate, EKG, and blood pressure in adults who already have existing cardiac disease and elderly patients.<xref ref-type="bibr" rid="article-25988.r28">[28]</xref></p>
        <p>Monitor for improvement/worsening of depression using questionnaires such as PHQ-9 (Patient Health Questionnaire-9), which are patient-reported outcomes<xref ref-type="bibr" rid="article-25988.r30">[30]</xref>,&#x000a0;and the Montgomery-Asberg Depression Rating Scale (MADRS), which is based on clinical judgment.<xref ref-type="bibr" rid="article-25988.r31">[31]</xref>&#x000a0;Integration of clinical decision support&#x000a0;tools (CDS tools) in EHR can improve the administration of questionnaires and management of depression.<xref ref-type="bibr" rid="article-25988.r32">[32]</xref></p>
      </sec>
      <sec id="article-25988.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Like many other TCAs, the toxicity of nortriptyline can be very harmful to the body. During an overdose, there is a blockade of the following receptors: sodium channels (fast) in the heart, muscarinic Ach receptors (central and peripheral), alpha-1 receptors in the periphery, and H1 and GABA-A in the central nervous system. Therefore, the most crucial initial step when assessing a patient with toxicity is ensuring the patient&#x000a0;can adequately breathe. Intubation is usually mandatory for airway protection and proper ventilation. In addition, the clinician can administer IV fluids for hypotension.</p>
        <p>Additionally, sodium bicarbonate is the recommended treatment for patients with prolonged QRS (greater than 100 milliseconds) or ventricular arrhythmia. The sodium bicarbonate dosage depends on the patient's weight, usually 1 to 2 mEq/kg.&#x000a0;Arrhythmias not responding to sodium bicarbonate therapy may&#x000a0;need&#x000a0;lidocaine, phenytoin, or bretylium. TCAs can also cause seizures. These can have treatment with benzodiazepines such as lorazepam 2 mg or diazepam 5 mg, administered through the intravenous (IV) route. Treatment with activated charcoal for gastrointestinal decontamination is only indicated in patients who present within 2 hours of overdose (1 g/kg). Although there is a strong blockage of muscarinic acetylcholine receptors, physostigmine is contraindicated in the event of TCA toxicity as it can cause adverse cardiac effects such as cardiac arrest.<xref ref-type="bibr" rid="article-25988.r28">[28]</xref>&#x000a0;The principles of management of&#x000a0;pediatric&#x000a0;overdose&#x000a0;are similar. However, It is recommended that the&#x000a0;clinician contact the local poison control center for specific pediatric treatment.</p>
      </sec>
      <sec id="article-25988.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Interprofessional healthcare team members, including clinicians, psychiatrists, nurse practitioners and physician assistants, nurses, and pharmacists, should be aware that nortriptyline is no longer a first-line choice for its indicated conditions. There are many better and safer antidepressants on the market. The drug has many side effects, which are often not well tolerated.<xref ref-type="bibr" rid="article-25988.r33">[33]</xref>&#x000a0;</p>
        <p>However, when a patient is taking nortriptyline, all interprofessional team members should contribute from their individual disciplines to ensure proper dosing, the absence of drug-drug interactions, and participate in patient monitoring and education, to drive optimal outcomes with minimal adverse events. Every team member is responsible for monitoring and counseling the patient and must be alert for signs of therapeutic failure, possible drug interactions, or adverse events, including toxicity. If they note an issue with the patient, they should report these to the other team members and document their observations in the patient's medical record. A randomized controlled trial aimed at the clinical effectiveness of collaborative care in managing patients with moderate to severe depression showed optimistic results. Coordinated care between health care providers had continued promising&#x000a0;results up to one year after initiation of the depression treatment and was preferred by patients.<xref ref-type="bibr" rid="article-25988.r34">[34]</xref>&#x000a0;[Level 2]</p>
      </sec>
      <sec id="article-25988.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=25988&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=25988">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/25988/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=25988">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-25988.s11">
        <title>References</title>
        <ref id="article-25988.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yamamoto</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Conchon Costa</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Lauretti</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>de Moraes</surname>
                <given-names>NV</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice.</article-title>
            <source>Pharmacogenomics</source>
            <year>2019</year>
            <month>Aug</month>
            <volume>20</volume>
            <issue>13</issue>
            <fpage>971</fpage>
            <page-range>971-982</page-range>
            <pub-id pub-id-type="pmid">31486733</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Asrar</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Kumari</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sekhar</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Bhansali</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bansal</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Relative Efficacy and Safety of Pharmacotherapeutic Interventions for Diabetic Peripheral Neuropathy: A Systematic Review and Bayesian Network Meta-Analysis.</article-title>
            <source>Pain Physician</source>
            <year>2021</year>
            <month>Jan</month>
            <volume>24</volume>
            <issue>1</issue>
            <fpage>E1</fpage>
            <page-range>E1-E14</page-range>
            <pub-id pub-id-type="pmid">33400429</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haviv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sharav</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Almoznino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Benoliel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Nortriptyline Compared to Amitriptyline for the Treatment of Persistent Masticatory Myofascial Pain.</article-title>
            <source>J Oral Facial Pain Headache</source>
            <year>2019</year>
            <season>Winter</season>
            <volume>33</volume>
            <issue>1</issue>
            <fpage>7&#x02013;13</fpage>
            <pub-id pub-id-type="pmid">30129937</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haviv</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zadik</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Sharav</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Benoliel</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment.</article-title>
            <source>J Oral Facial Pain Headache</source>
            <year>2014</year>
            <season>Winter</season>
            <volume>28</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-60</page-range>
            <pub-id pub-id-type="pmid">24482788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mallick-Searle</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Snodgrass</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Brant</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Postherpetic neuralgia: epidemiology, pathophysiology, and pain management pharmacology.</article-title>
            <source>J Multidiscip Healthc</source>
            <year>2016</year>
            <volume>9</volume>
            <fpage>447</fpage>
            <page-range>447-454</page-range>
            <pub-id pub-id-type="pmid">27703368</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Howes</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hartmann-Boyce</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Livingstone-Banks</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Lindson</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants for smoking cessation.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2020</year>
            <month>Apr</month>
            <day>22</day>
            <volume>4</volume>
            <issue>4</issue>
            <fpage>CD000031</fpage>
            <pub-id pub-id-type="pmid">32319681</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Burch</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants for Preventive Treatment of Migraine.</article-title>
            <source>Curr Treat Options Neurol</source>
            <year>2019</year>
            <month>Mar</month>
            <day>21</day>
            <volume>21</volume>
            <issue>4</issue>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">30895388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Song</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Choksawad</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Franco</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>The Effectiveness of Nortriptyline and Tolerability of Side Effects in Neurogenic Cough Patients.</article-title>
            <source>Ann Otol Rhinol Laryngol</source>
            <year>2021</year>
            <month>Jul</month>
            <volume>130</volume>
            <issue>7</issue>
            <fpage>781</fpage>
            <page-range>781-787</page-range>
            <pub-id pub-id-type="pmid">33218281</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bohren</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Tessier</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Megat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Petitjean</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Hugel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Daniel</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Kremer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fournel</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hein</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schlichter</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Freund-Mercier</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Yalcin</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Barrot</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants suppress neuropathic pain by a peripheral &#x003b2;2-adrenoceptor mediated anti-TNF&#x003b1; mechanism.</article-title>
            <source>Neurobiol Dis</source>
            <year>2013</year>
            <month>Dec</month>
            <volume>60</volume>
            <fpage>39</fpage>
            <page-range>39-50</page-range>
            <pub-id pub-id-type="pmid">23978467</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>G&#x000f3;mez-Coronado</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>AJ</given-names>
              </name>
              <name>
                <surname>Berk</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Dodd</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking.</article-title>
            <source>Pharmacotherapy</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>38</volume>
            <issue>2</issue>
            <fpage>235</fpage>
            <page-range>235-258</page-range>
            <pub-id pub-id-type="pmid">29250815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Caldara</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Marmiroli</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Known Antimicrobials Versus Nortriptyline in <italic>Candida albicans</italic>: Repositioning an Old Drug for New Targets.</article-title>
            <source>Microorganisms</source>
            <year>2020</year>
            <month>May</month>
            <day>15</day>
            <volume>8</volume>
            <issue>5</issue>
            <pub-id pub-id-type="pmid">32429222</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Szegedi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>WT</given-names>
              </name>
              <name>
                <surname>van Willigenburg</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>van der Meulen</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stassen</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Thase</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>344</fpage>
            <page-range>344-53</page-range>
            <pub-id pub-id-type="pmid">19254516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Nortriptyline</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2022</year>
            <month>4</month>
            <day>18</day>
            <pub-id pub-id-type="pmid">30000235</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hicks</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Sangkuhl</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Swen</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Ellingrod</surname>
                <given-names>VL</given-names>
              </name>
              <name>
                <surname>M&#x000fc;ller</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Shimoda</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bishop</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Kharasch</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Skaar</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Gaedigk</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dunnenberger</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>TE</given-names>
              </name>
              <name>
                <surname>Caudle</surname>
                <given-names>KE</given-names>
              </name>
              <name>
                <surname>Stingl</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>102</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-44</page-range>
            <pub-id pub-id-type="pmid">27997040</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weinshilboum</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Pharmacogenomics: Precision Medicine and Drug Response.</article-title>
            <source>Mayo Clin Proc</source>
            <year>2017</year>
            <month>Nov</month>
            <volume>92</volume>
            <issue>11</issue>
            <fpage>1711</fpage>
            <page-range>1711-1722</page-range>
            <pub-id pub-id-type="pmid">29101939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spielmans</surname>
                <given-names>GI</given-names>
              </name>
              <name>
                <surname>Spence-Sing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Parry</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Duty to Warn: Antidepressant Black Box Suicidality Warning Is Empirically Justified.</article-title>
            <source>Front Psychiatry</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">32116839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hussein</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Digges</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Doogue</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rowett</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Agar</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sinnarajah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Kain</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Allan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Boland</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Currow</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Pharmacovigilance in hospice/palliative care: Net effect of amitriptyline or nortriptyline on neuropathic pain: UTS/IMPACCT Rapid programme international consecutive cohort.</article-title>
            <source>Palliat Med</source>
            <year>2022</year>
            <month>Jun</month>
            <volume>36</volume>
            <issue>6</issue>
            <fpage>938</fpage>
            <page-range>938-944</page-range>
            <pub-id pub-id-type="pmid">35403513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richa</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yazbek</surname>
                <given-names>JC</given-names>
              </name>
            </person-group>
            <article-title>Ocular adverse effects of common psychotropic agents: a review.</article-title>
            <source>CNS Drugs</source>
            <year>2010</year>
            <month>Jun</month>
            <volume>24</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-26</page-range>
            <pub-id pub-id-type="pmid">20443647</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ancuceanu</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dinu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Furtunescu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Boda</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>An inventory of medicinal products causing skin rash: Clinical and regulatory lessons.</article-title>
            <source>Exp Ther Med</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>5061</fpage>
            <page-range>5061-5071</page-range>
            <pub-id pub-id-type="pmid">31798726</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nelson</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Sweeney</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Exacerbation of psychosis by tricyclic antidepressants in delusional depression.</article-title>
            <source>Am J Psychiatry</source>
            <year>1979</year>
            <month>Apr</month>
            <volume>136</volume>
            <issue>4B</issue>
            <fpage>574</fpage>
            <page-range>574-6</page-range>
            <pub-id pub-id-type="pmid">426146</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gitlin</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Antidepressants in bipolar depression: an enduring controversy.</article-title>
            <source>Int J Bipolar Disord</source>
            <year>2018</year>
            <month>Dec</month>
            <day>01</day>
            <volume>6</volume>
            <issue>1</issue>
            <fpage>25</fpage>
            <pub-id pub-id-type="pmid">30506151</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hill</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coupland</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Morriss</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Arthur</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Moore</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hippisley-Cox</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant use and risk of epilepsy and seizures in people aged 20 to 64&#x000a0;years: cohort study using a primary care database.</article-title>
            <source>BMC Psychiatry</source>
            <year>2015</year>
            <month>Dec</month>
            <day>17</day>
            <volume>15</volume>
            <fpage>315</fpage>
            <pub-id pub-id-type="pmid">26678837</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Elsamadisi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Sclafani</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Eche</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Delayed Cardiotoxicity From a Massive Nortriptyline Overdose Requiring Prolonged Treatment.</article-title>
            <source>J Pharm Pract</source>
            <year>2020</year>
            <month>Aug</month>
            <volume>33</volume>
            <issue>4</issue>
            <fpage>543</fpage>
            <page-range>543-547</page-range>
            <pub-id pub-id-type="pmid">30983469</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gabriel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>V</given-names>
              </name>
            </person-group>
            <article-title>Antidepressant discontinuation syndrome.</article-title>
            <source>CMAJ</source>
            <year>2017</year>
            <month>May</month>
            <day>29</day>
            <volume>189</volume>
            <issue>21</issue>
            <fpage>E747</fpage>
            <pub-id pub-id-type="pmid">28554948</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <article-title>Drugs for Depression.</article-title>
            <source>Med Lett Drugs Ther</source>
            <year>2020</year>
            <month>Feb</month>
            <day>24</day>
            <volume>62</volume>
            <issue>1592</issue>
            <fpage>25</fpage>
            <page-range>25-32</page-range>
            <pub-id pub-id-type="pmid">32320387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gillman</surname>
                <given-names>PK</given-names>
              </name>
            </person-group>
            <article-title>Tricyclic antidepressant pharmacology and therapeutic drug interactions updated.</article-title>
            <source>Br J Pharmacol</source>
            <year>2007</year>
            <month>Jul</month>
            <volume>151</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-48</page-range>
            <pub-id pub-id-type="pmid">17471183</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Volpi-Abadie</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Serotonin syndrome.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Winter</season>
            <volume>13</volume>
            <issue>4</issue>
            <fpage>533</fpage>
            <page-range>533-40</page-range>
            <pub-id pub-id-type="pmid">24358002</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r28">
          <label>28</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Merwar</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Gibbons</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Hosseini</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Saadabadi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Nortriptyline</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>6</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">29489270</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Meredith</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Thapa</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Hall</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Murray</surname>
                <given-names>KT</given-names>
              </name>
            </person-group>
            <article-title>Cyclic antidepressants and the risk of sudden cardiac death.</article-title>
            <source>Clin Pharmacol Ther</source>
            <year>2004</year>
            <month>Mar</month>
            <volume>75</volume>
            <issue>3</issue>
            <fpage>234</fpage>
            <page-range>234-41</page-range>
            <pub-id pub-id-type="pmid">15001975</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kroenke</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Spitzer</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>JB</given-names>
              </name>
            </person-group>
            <article-title>The PHQ-9: validity of a brief depression severity measure.</article-title>
            <source>J Gen Intern Med</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>9</issue>
            <fpage>606</fpage>
            <page-range>606-13</page-range>
            <pub-id pub-id-type="pmid">11556941</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Devine</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>KF</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Saretsky</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Jamieson</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <article-title>Evidence to Support Montgomery-Asberg Depression Rating Scale Administration Every 24 Hours to Assess Rapid Onset of Treatment Response.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>77</volume>
            <issue>12</issue>
            <fpage>1681</fpage>
            <page-range>1681-1686</page-range>
            <pub-id pub-id-type="pmid">28086004</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maten</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Kroehl</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Loeb</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Bhat</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ota</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Billups</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Schilling</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Heckman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Reingardt</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Trinkley</surname>
                <given-names>KE</given-names>
              </name>
            </person-group>
            <article-title>An evaluation of clinical decision support tools for Patient Health Questionnaire-9 administration.</article-title>
            <source>Ment Health Clin</source>
            <year>2021</year>
            <month>Sep</month>
            <volume>11</volume>
            <issue>5</issue>
            <fpage>267</fpage>
            <page-range>267-273</page-range>
            <pub-id pub-id-type="pmid">34621601</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Riediger</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuster</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Barlinn</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Maier</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Weitz</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Siepmann</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Adverse Effects of Antidepressants for Chronic Pain: A Systematic Review and Meta-analysis.</article-title>
            <source>Front Neurol</source>
            <year>2017</year>
            <volume>8</volume>
            <fpage>307</fpage>
            <pub-id pub-id-type="pmid">28769859</pub-id>
          </element-citation>
        </ref>
        <ref id="article-25988.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richards</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Hill</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Gask</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Lovell</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chew-Graham</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bower</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cape</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pilling</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Araya</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kessler</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bland</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Green</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gilbody</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Manning</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hughes-Morley</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Barkham</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Clinical effectiveness of collaborative care for depression in UK primary care (CADET): cluster randomised controlled trial.</article-title>
            <source>BMJ</source>
            <year>2013</year>
            <month>Aug</month>
            <day>19</day>
            <volume>347</volume>
            <fpage>f4913</fpage>
            <pub-id pub-id-type="pmid">23959152</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
